SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Josephine Baker

PatientJosephine Baker
Date of birth1963-06-03
IdentifiersMRN HR-ML049-SYN; SSN (made up) 000-49-3172
Document date2026-10-20
AuthorColette Ashby-Nwosu, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-month review: antiplatelet plan, blood pressure and screening results. [S]

History of Present Illness

Ms. Baker returns five weeks after her preventive visit. She has sung and danced in six concerts over the past month, resting between shows, without chest pain, breathlessness or palpitations, and she has not needed nitroglycerin. Her home blood pressure averages 120/74. She has had no further nosebleeds and no other bleeding. Her screening results: the FIT was negative, the mammogram was normal, and the hepatitis C and HIV tests were negative. The bone density scan showed osteopenia (lowest T-score -1.7 at the femoral neck) with a ten-year fracture risk below the level at which medicine is advised. The optometrist found no disease. She asks how long she must take clopidogrel. [S]

ElementDetail
PerformingSix concerts in a month without symptoms
Home blood pressureAverage 120/74 mmHg
ScreeningFIT, mammogram, hepatitis C and HIV negative; osteopenia below the treatment threshold
Seattle Angina Questionnaire-796

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations or lightheadedness
RespiratoryNegativeNo breathlessness on stage or on stairs
Hematologic/lymphaticNegativeNo bleeding or unusual bruising
MusculoskeletalNegativeKnees stiff after long shows; no falls

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Ticagrelor 90 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-03-24 to 2026-04-28completedS
Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet dailyOne tablet daily after a 600 mg loading doseOral route2026-04-28activeS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Lisinopril 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24 to 2026-04-28completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-28activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route2026-03-24activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-20Body height168cmS
2026-10-20Body weight60.6kgS
2026-10-20Body mass index (BMI) [Ratio]21.5kg/m2S
2026-10-20Systolic blood pressure122mm[Hg]S
2026-10-20Diastolic blood pressure74mm[Hg]S
2026-10-20Heart rate58/minS
2026-10-20Respiratory rate14/minS
2026-10-20Body temperature36.6CelS
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-20Hemoglobin [Mass/volume] in Blood12.4g/dL11.6-15 g/dLNormalS
2026-10-20Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-20Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-20Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-10-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M78mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-20Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-10-20Overall summary score [SAQ]96{score}S

Physical Exam

Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/74, pulse 58; weight 60.6 kg
CardiovascularRegular rhythm; no murmur
RespiratoryClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and tiredness since discharge three weeks after the heart attack, without chest pain at rest; cause to be determined (heart function, ischemia, anemia, medicine effect or deconditioning)resolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology attributed it to ticagrelor.
Coronary artery disease after a non-ST-elevation myocardial infarction three weeks before intake, treated with one drug-eluting stent to the right coronary artery; synthetic modern episode linked to the documented heart attack of March 1969activeconfirmed I25.10S — Synthetic modern diagnosis; the 1969 heart attack remains D in the history.
High blood pressure, found during the hospital stay for the heart attackactiveconfirmed I10S — Synthetic modern diagnosis; no claim about her real blood pressure.
Absence of the uterus after an emergency hysterectomy at about 35, during a long, grave illness after the loss of a pregnancy; whether the ovaries were removed is not known; counted as a possible early menopause when weighing her cardiovascular riskactiveprovisional Z90.710S — Synthetic modern status linked to the retrospective account of a hysterectomy in 1941 or 1942; the operation itself rests on one secondary source.
Breathlessness from ticagrelor: a common, harmless side effect, resolved after the change to clopidogrelresolvedconfirmed T45.525AS — Synthetic diagnosis at the second visit; resolved at the third visit after the switch.
Raised lipoprotein(a), 172 nmol/L, an inherited risk-enhancing factoractiveconfirmed E78.41S — Synthetic result measured once at the second visit.
Financial strain: heavy debts after the loss of her home and estate, with income only from performing, which she has stopped while she recoversactiveconfirmed Z59.86S — Synthetic social need anchored to her documented debts and the loss of Les Milandes.
Anterior nosebleed from the left side of the nose, lasting about 25 minutes, in dry weather on aspirin and clopidogrel; stopped with pressure; no further bleedingresolvedconfirmed R04.0S — Synthetic intercurrent problem at an unscheduled visit; it follows from dual antiplatelet therapy and does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure (seated, average of two readings; home readings)Every visitCompleted today122/74 mmHg; home average 120/74
ExaminationWeight, BMI and physical activityEvery visitCompleted today60.6 kg; six concerts in a month
Medication safetyAdherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitorEvery visitCompleted todayNo missed doses; clopidogrel to stop at twelve months, aspirin to continue
Medication safetyBleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated)Every visitCompleted todayNo bleeding since the nosebleed in June; hemoglobin 12.4 g/dL, platelets not repeated
LaboratoryMetabolic panel (potassium, creatinine, eGFR) on an ACE inhibitorEvery six to twelve months when stableCompleted todaySodium 139, potassium 4.5, creatinine 0.84 mg/dL (eGFR 78), glucose 93
LaboratoryLipid panelEvery three to twelve months when stableUp to dateLDL 62 mg/dL in July; next at about one year
LaboratoryHemoglobin A1c (no diabetes)Yearly screeningUp to date5.6% in April; due at one year
SurveyAngina status (Seattle Angina Questionnaire-7)At intake and every few months in the first yearCompleted today96
SurveyDepression screen (PHQ-2, then PHQ-9)After the infarction and periodicallyUp to datePHQ-2 0 at the preventive visit
ExaminationStress testing or repeat angiographyNot for routine surveillanceNot indicatedNo symptoms; routine repeat testing is not recommended
ImagingEchocardiogram for left ventricular functionAfter the infarction if not done or if function was reduced; then only with clinical changeNot indicatedNo clinical change
ExaminationInfluenza, COVID-19 and RSV vaccination reviewYearlyCompleted todayInfluenza, COVID-19 and PCV20 at the preventive visit; RSV, zoster dose 1 and Tdap today
Self-managementSelf-management: chest-pain action plan, nitroglycerin, women's warning symptomsEvery visitCompleted todayNitroglycerin in the dressing room; not needed

Goal progress:

Immunizations given today: Respiratory syncytial virus vaccine, single dose; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]

Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)

Follow-up: RSV vaccine, zoster dose 1 and Tdap given today; second zoster dose in two to six months. Review in about three months, before clopidogrel stops at twelve months. Call 911 for chest pain not relieved five minutes after one nitroglycerin. [S]